Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The FDA has approved a new nonstimulant drug, known as viloxazine (Qelbree), to treat attention-deficit/hyperactivity disorder (ADHD) in children aged 6 to 17 years, the manufacturer has announced.
In clinical trials, children given viloxazine, a selective norepinephrine reuptake inhibitor, had greater improvement on an ADHD symptom severity scale, compared with those given placebo.
Children taking the drug should be monitored for suicidal thoughts and behaviors, especially after treatment initiation and dosing changes. Suicidality rates were higher in clinical trials among those taking viloxazine.
The drug shouldn't be given concomitantly or within 14 days of stopping a monoamine oxidase inhibitor because of elevated risk for hypertensive crisis.
Comment
LINK(S):
Manufacturer's news release (Free PDF)
Prescribing information (Free PDF)
Background: Physician's First Watch coverage of analysis of ADHD drugs (Free)